Published in Br J Cancer on July 07, 2003
Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. J Clin Oncol (2011) 1.26
Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol (2009) 1.20
Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer (2007) 1.14
Chemotherapy outpatients' unplanned presentations to hospital: a retrospective study. Support Care Cancer (2010) 1.11
The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer (2013) 1.05
Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. Support Care Cancer (2007) 0.90
Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients. Support Care Cancer (2012) 0.90
Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer (2008) 0.88
Management of febrile neutropenia in the United Kingdom: time for a national trial? Br J Cancer (2005) 0.87
Health-related quality of life anticipated with different management strategies for paediatric febrile neutropaenia. Br J Cancer (2011) 0.86
Risk-adapted strategy for the management of febrile neutropenia in cancer patients. Support Care Cancer (2007) 0.85
Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. Br J Cancer (2011) 0.84
Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support Care Cancer (2009) 0.82
A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings. Br J Cancer (2010) 0.80
Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6. Support Care Cancer (2015) 0.77
Oral antibiotic administration and early hospital discharge is a safe and effective alternative for treatment of low-risk neutropenic fever. Cancer Treat Rev (2003) 0.75
Eliciting patients' preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment. Support Care Cancer (2012) 0.75
The time has come for new models in febrile neutropenia: a practical demonstration of the inadequacy of the MASCC score. Clin Transl Oncol (2017) 0.75
The hospital anxiety and depression scale. Acta Psychiatr Scand (1983) 121.58
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 38.99
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol (1993) 18.75
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis (2002) 7.81
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer (1990) 5.34
Fungal infections complicating acute leukemia. J Chronic Dis (1966) 4.07
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol (2000) 3.69
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med (1999) 3.02
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med (1986) 2.26
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis (1997) 2.14
Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol (1992) 1.86
Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis (1997) 1.84
Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol (1994) 1.75
Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med (1995) 1.75
The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med (1988) 1.41
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother (1995) 1.31
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer (1993) 1.25
A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med (1992) 1.21
Controversies in the management of febrile neutropenic cancer patients. Cancer Invest (1988) 1.10
Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer (1994) 1.10
Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Ann Oncol (1991) 0.94
Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clin Infect Dis (2002) 0.92
Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet (1992) 0.92
Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis (1991) 0.88
Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics (1995) 0.88
Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Support Care Cancer (2001) 0.87
The costs of treating febrile neutropenia in six U.K. Hospitals. Eur J Cancer (1993) 0.83
Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients. Support Care Cancer (2000) 0.81
Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol (2000) 0.80
Hantavirus outbreak yields to PCR. Science (1993) 9.80
Dispute slows paper on "remarkable" vaccine. Science (1995) 5.83
Nonmuscle actin-binding proteins. Annu Rev Cell Biol (1985) 5.46
Gene therapy death prompts review of adenovirus vector. Science (1999) 4.33
National field evaluation of a defined substrate method for the simultaneous enumeration of total coliforms and Escherichia coli from drinking water: comparison with the standard multiple tube fermentation method. Appl Environ Microbiol (1988) 3.83
Genome size and the proportion of repeated nucleotide sequence DNA in plants. Biochem Genet (1974) 3.66
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol (1999) 3.48
When does intellectual passion become conflict of interest? Science (1992) 3.30
Whose genome is it, anyway? Science (1996) 3.29
Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA (1999) 3.11
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer (1992) 2.91
National field evaluation of a defined substrate method for the simultaneous detection of total coliforms and Escherichia coli from drinking water: comparison with presence-absence techniques. Appl Environ Microbiol (1989) 2.88
Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med (1985) 2.73
Clinical trials. Planned Ritalin trial for tots heads into uncharted waters. Science (2000) 2.70
New Zealand's leap into gene therapy. Science (1996) 2.67
Lyme disease. NIH gears up to test a hotly disputed theory. Science (1995) 2.65
Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J Gen Virol (1994) 2.53
Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun (1995) 2.48
Full-scale studies of factors related to coliform regrowth in drinking water. Appl Environ Microbiol (1996) 2.47
Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy. Nat Genet (1996) 2.46
Allen Roses: from 'street fighter' to corporate insider. Science (1998) 2.37
Bermuda rules: community spirit, with teeth. Science (2001) 2.36
Mr 26,000 antigen of Schistosoma japonicum recognized by resistant WEHI 129/J mice is a parasite glutathione S-transferase. Proc Natl Acad Sci U S A (1986) 2.35
Enumeration of total coliforms and Escherichia coli from source water by the defined substrate technology. Appl Environ Microbiol (1990) 2.30
Structural constraints on RNA virus evolution. J Virol (1999) 2.24
Drug firms to create public database of genetic mutations. Science (1999) 2.14
Colorimetric detection of specific DNA segments amplified by polymerase chain reactions. Proc Natl Acad Sci U S A (1989) 2.14
Despite anxiety, NIH begins merging neuroscience panels. Science (1996) 2.04
Startling revelations in UC-Genentech battle. Science (1999) 2.04
Intensive treatment of multiple myeloma and criteria for complete remission. Lancet (1989) 2.04
Alternative medicine. Bastions of tradition adapt to alternative medicine. Science (2000) 2.04
Supreme Court to weigh science. Science (1993) 2.03
A small angle light scattering device for planar connective tissue microstructural analysis. Ann Biomed Eng (1997) 2.02
Why the success of dentistry's charitable foundation should matter to you. J Can Dent Assoc (2001) 2.02
NIH panel urges overhaul of the rating system for grants. Science (1996) 2.01
Policy on DNA research troubles tissue bankers. Science (1996) 2.00
Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol (2007) 1.98
Extreme heterogeneity of Ty1-copia group retrotransposons in plants. Mol Gen Genet (1992) 1.81
Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology (1987) 1.81
Epidemiology. Search for a killer: focus shifts from fat to hormones. Science (1993) 1.77
Scientific misconduct. How prevalent is fraud? That's a million-dollar question. Science (2000) 1.73
External ocular motor palsies in ophthalmic zoster: a review. Br J Ophthalmol (1977) 1.73
A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol (1989) 1.72
How tobacco companies ensure prime placement of their advertising and products in stores: interviews with retailers about tobacco company incentive programmes. Tob Control (2003) 1.71
Neurotoxicity among pesticide applicators exposed to organophosphates. Occup Environ Med (1995) 1.71
Too radical for NIH? Try DARPA. Science (1997) 1.68
Development of a model of the tobacco industry's interference with tobacco control programmes. Tob Control (2003) 1.66
Heterosexual transmission of hepatitis C virus. Lancet (1993) 1.65
Mood changes and "on-off" phenomena in Parkinson's disease. Mov Disord (1990) 1.59
Varmus proposes to scrap the RAC. Science (1996) 1.57
Snipping away at genome patenting. Science (1997) 1.57
Data sharing: a declining ethic? Science (1990) 1.56
The mouse that prompted a roar. Science (1997) 1.55
A high-stakes gamble on genome sequencing. Science (1999) 1.51
Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifications based upon sequence similarity. J Gen Virol (1996) 1.46
Congenital defects and electric bed heating in New York State: a register-based case-control study. Am J Epidemiol (1992) 1.46
Toxicology goes molecular. Science (1993) 1.46
Less hype, more biology needed for gene therapy. Science (1995) 1.45
In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther (1996) 1.45
A is for apple, Alar, and ... alarmist? Science (1991) 1.44
The human gene hunt scales up. Science (1996) 1.43
Fallout from Pacific tests reaches Congress. Science (1989) 1.42
Varmus orders up a review of the science of gene therapy. Science (1995) 1.42
Six-month success of intracoronary stenting for anomalous coronary arteries associated with myocardial ischemia. Am J Cardiol (2000) 1.42
The role of the practice nurse in the management of depression in general practice: treatment adherence to antidepressant medication. Psychol Med (1993) 1.41
Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort. J Virol (1998) 1.41
A clash over standards for scientific records. Science (1990) 1.40
Academy panel raises radiation risk estimate. Science (1990) 1.40
A bitter battle over insulin gene. Science (1997) 1.40
Is data-hoarding slowing the assault on pathogens? Science (1997) 1.40
Medicine. Fast technology drives new world of newborn screening. Science (2001) 1.40
Trial set to focus on peer review. Science (1996) 1.40
The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer (1996) 1.40
NIH told to reconsider crime meeting. Science (1993) 1.39
Toward a definition of health services management: a humanist orientation. Int J Health Serv (1974) 1.39
Anxiety hits mental health institute. Science (1994) 1.39
NIMH: caught in the line of fire without a general. Science (1995) 1.39
Financial conflict. Universities puncture modest regulatory trial balloon. Science (2001) 1.39
Rules on embryo research due out. Science (1994) 1.39
Paleoanthropology gets physical. Science (1990) 1.39
Panel urges cloning ethics board. Science (1997) 1.38
Management overhaul at Johns Hopkins. Science (1995) 1.38
Single agent activity of carboplatin in patients with previously untreated non-seminomatous germ cell tumours. Ann Oncol (1992) 1.38
Artificial heart: the beat goes on. Science (1991) 1.38
Human Genome Project. Sequencers endorse plan for a draft in 1 year. Science (1999) 1.36
Gene therapy on trial. Science (2000) 1.34
Simplified colorimetric analysis of polymerase chain reactions: detection of HIV sequences in AIDS patients. Gene (1990) 1.34
Is everyone in agreement? An exploration of within-group agreement in employee perceptions of the work environment. J Appl Psychol (2001) 1.30
Role of plasma gelsolin and the vitamin D-binding protein in clearing actin from the circulation. J Clin Invest (1986) 1.30
Non-secretory multiple myeloma: a report of 13 cases with a review of the literature. Hematol Oncol (1987) 1.29
The aortic valve microstructure: effects of transvalvular pressure. J Biomed Mater Res (1998) 1.29
NIH launches the final push to sequence the genome. Science (1996) 1.27
Device choice and experience level in endoscopic foreign object retrieval: an in vivo study. Gastrointest Endosc (1997) 1.25
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. J Clin Oncol (1990) 1.25
Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann N Y Acad Sci (1991) 1.24
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer (2002) 1.24
Defined substrate technology method for rapid and specific simultaneous enumeration of total coliforms and Escherichia coli from water: collaborative study. J Assoc Off Anal Chem (1991) 1.24
Varmus circulates proposal for NIH-backed online venture. Science (1999) 1.22
The quantitative separation of 3',5'-cyclic adenosine monophosphate, adenosine-5'-monophosphate, adenosine-5'-diphosphate, and adenosine-5'-triphosphate by ion-exchange chromatography on diethylaminoethyl sephadex. J Chromatogr (1970) 1.22